NASDAQ:ONCS - OncoSec Medical Incorporated
$0.64
 $0.02
+3.10%
2:10PM EDT
2019-02-15
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ONCS     avg for
industry  
  avg for
sector  
42 stocks weight:  11. 59   0. 00   0. 00  
42 stocks rank:  3. 88 K 1. 86 K 1. 09 K
# analyst opinions:  2. 00   14. 92   14. 43  
mean recommendation:  2. 30   1. 91   1. 93  

quick ratio:  5. 03   5. 37   1. 81  
current ratio:  5. 41   5. 69   2. 19  

target price low:  0. 40   88. 97   117. 82  
target price avg:  0. 50   115. 19   141. 96  
target price high:  0. 95   143. 40   163. 16  
1-yr high:  2. 15   124. 30   142. 77  
last close:  0. 62   101. 85   127. 84  
50-day avg:  0. 70   98. 27   122. 46  
200-day avg:  1. 23   99. 72   122. 70  
1-yr low:  0. 55   78. 19   100. 16  
volume:  373. 64 K 2. 38 M 4. 64 M
50-day avg volume:  1. 17 M 3. 31 M 4. 94 M
200-day avg volume:  1. 16 M 3. 23 M 4. 28 M

1-day return:  -3. 13 % 0. 22 % 0. 48 %
this week return:  3. 33 % 1. 77 % 2. 01 %
12-wk return:  -34. 74 % 6. 56 % 3. 33 %
52-wk return:  -65. 91 % -2. 23 % 14. 35 %

enterprise value (EV):  10. 23 M 55. 17 B 104. 51 B
market cap:  39. 20 M 49. 01 B 96. 46 B
EBITDA:  -37. 38 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -0. 27   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -40. 81 M 2. 37 B 3. 58 B

shares outstanding:  64. 51 M 607. 99 M 1. 22 B
shares:  52. 40 M 605. 53 M 1. 15 B
shares short:  2. 99 M 11. 62 M 12. 55 M
shares short prior month:  3. 83 M 11. 95 M 13. 44 M
short ratio:  4. 34   4. 82   3. 10  
short % of float:  5. 09 % 6. 19 % 2. 82 %
total cash/share:  0. 44   12. 02   11. 46  
total cash:  28. 47 M 7. 41 B 7. 37 B
free cash flow:  -10. 97 M 95. 99 M 2. 04 B
operating cash flow:  -24. 92 M 164. 74 M 3. 04 B

book value:  0. 42   14. 43   28. 26  
price/book:  1. 47   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -50. 00 % --- ---
1-yr mean volatility:  -0. 27 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 84   3. 03   4. 09  
forward EPS:  -0. 71   4. 33   6. 99  
P/E:  -0. 73   6. 11   26. 91  
forward P/E:  -0. 85   8. 38   10. 48  
PE/G:  0. 01   0. 37   5. 61  
growth:  -53. 01 % 683. 72 % 104. 79 %
earnings high:  -0. 16   1. 27   1. 66  
earnings avg:  -0. 17   1. 01   1. 53  
earnings low:  -0. 18   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -92. 59 % -3. 27 % 3. 81 %
return on equity:  -210. 71 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  0. 63   1. 21   0. 93  
sharpe (1yr):  -0. 75   0. 06   0. 98  

held % insiders:  17. 16 % 6. 46 % 3. 21 %
held % institutions:  11. 89 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ONCS
.        + 0 =             0 :: INITIAL WEIGHT
.  + 166.745 =       166.745 :: inverse volume-to-price addition
.  + 134.972 =       301.717 :: spline projection addition
.  - 197.155 =       104.562 :: poor performance penalty
.    x 0.586 =        61.251 :: one-year gains+dividend factor
.    x 3.861 =       236.489 :: 13 weeks' performance factor
.    x 1.492 =       352.957 :: industry recommendation factor
.    x 1.784 =       629.524 :: symbol recommendation factor
.    x 0.991 =       623.696 :: return on assets factor
.    x 0.979 =       610.554 :: return on equity factor
.    x 2.951 =      1801.575 :: current ratio factor
.    x 1.117 =      2012.573 :: quick ratio factor
.    x 1.109 =      2232.428 :: short ratio factor
.    x 2.015 =      4497.655 :: price-to-book factor
.    x 2.173 =      9772.408 :: P/E weight
.    x 2.209 =      21586.85 :: PE/G factor
.     x 1.69 =     36489.986 :: beta factor
.    x 0.749 =     27314.357 :: sharpe factor
.     x 0.94 =     25687.286 :: target low factor
.    x 0.922 =     23684.254 :: target mean factor
.    x 1.073 =     25425.021 :: target high factor
.    x 1.066 =     27093.228 :: industry 12-weeks return
.    x 0.971 =     26296.176 :: "drift" penalty 3 days ago
.    x 0.984 =     25870.341 :: overall "drift" factor
.    x 0.998 =     25810.178 :: largest single-day jump factor
.     x 0.06 =      1558.586 :: low price factor
.      x 1.0 =       1558.69 :: factor hist industry gain for week 06
.   cubeRoot =        11.595 :: reduced for readability
.                     11.595 :: FINAL WEIGHT for NASDAQ:ONCS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org